Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus INFANT S ADVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus INFANT S ADVIL.
EC-NAPROSYN vs INFANT'S ADVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
500-1000 mg orally twice daily; maximum 1500 mg/day.
200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours).
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
NSAID
NSAID